newsfilter
← Latest News
GlobeNewswire·

Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform

  • Conexeu Sciences Inc. has initiated development of W.A.F.E.R.™, a fabricated collagen-based scaffold platform featuring two new formats: the W.A.F.E.R.™ Sheet & the W.A.F.E.R.™ Lattice.
  • The W.A.F.E.R.™ Sheet is designed as a flexible, lyophilized device intended to conform to broad wound surfaces at the point of care.
  • The W.A.F.E.R.™ Lattice is a lyophilized, three-dimensional scaffold engineered for large volumetric defects & can be shaped with a scalpel at the point of care.
  • These fabricated formats complement the company's lead flowable CXU™ device candidate, creating a three-format system targeting tunneled, broad surface, & large volumetric wound geometries.
  • Conexeu plans to submit an FDA 510(k) application for its flowable CXU™ device candidate in the first calendar quarter of 2027, subject to successful testing & manufacturing.
  • The W.A.F.E.R.™ Sheet & W.A.F.E.R.™ Lattice are in early-stage development, have not undergone preclinical evaluation, & will follow separate regulatory pathways with no set timing.
  • All current CXU™ platform studies remain preclinical using laboratory & animal models, with no data yet available for the new W.A.F.E.R.™ formats.
  • Conexeu holds all intellectual property rights to the CXU™ & W.A.F.E.R.™ platforms via a patent estate spanning over 40 jurisdictions.
  • The company targets large markets including wound care, periodontal applications, & soft-tissue restoration, with wound care identified as the first commercial indication upon FDA clearance.
Company
Conexeu
Keywords
Nasdaq:CNXU, Conexeu, Tissue Restoration, wound care, collagen-based scaffold